Ze Jing Pharmaceutical (688266.SH): Injectable human thyroid stimulating hormone approved to be listed on the market.

Zejing Pharmaceuticals (688266.SH) announced on January 8, 2026, that the company received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The company's independently developed new drug, injection of recombinant human thyroid stimulating hormone beta (formerly known as injection of recombinant human thyroid stimulating hormone, trademark: Zesuning), has been approved for market application. The approved indication for this product is: "Used for the collaborative diagnosis of differentiated thyroid cancer patients in the follow-up after total or near-total thyroidectomy, to conduct serum thyroglobulin (Tg) testing, with or without radioactive iodine (131I) whole-body scan (WBS) examination." The injection of recombinant human thyroid stimulating hormone beta is the first innovative product approved in China for accurate assessment of differentiated thyroid cancer after surgery.